Publications en collaboration avec des chercheurs de Medical University of Vienna (7)

2019

  1. Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (European Journal of Clinical Microbiology & Infectious Diseases, (2018), 37, 11, (2097-2106), 10.1007/s10096-018-3344-1)

    European Journal of Clinical Microbiology and Infectious Diseases

2018

  1. Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 37, Núm. 11, pp. 2097-2106

2016

  1. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 9, pp. 2405-2413

  2. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: An individual participant data meta-analysis

    Influenza and other Respiratory Viruses, Vol. 10, Núm. 3, pp. 192-204

2014

  1. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data

    The Lancet Respiratory Medicine, Vol. 2, Núm. 5, pp. 395-404

2012

  1. Estradiol impairs the Th17 immune response against candida albicans

    Journal of Leukocyte Biology, Vol. 91, Núm. 1, pp. 159-165

2006

  1. Respiratory tract infections: at-risk patients, who are they?. Implications for their management with levofloxacin

    International Journal of Antimicrobial Agents, Vol. 28, Núm. SUPPL. 2